Reata Pharmaceuticals closes CATALYST study of bardoxolone methyl for connective tissue disease-associated pulmonary arterial hypertension .
Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs , drug supply chain, and business operations. The Company announced measures… read more.